Cordlife Group Limited
1 Yishun Industrial Street 1 • A'Posh Bizhub • #06-01/09 • Singapore 768160
Phone (65) 6238 0808 • Fax (65) 6238 1108
Find Out More • info@cordlife.com • For Cordlife Parents • customercare@cordlife.com
Company Registration Number: 200102883E

PRESS RELEASE

Cordlife Narrows 9M2026 Net Loss by 18.2% to $5.8 million

- Net loss narrows on lower operating expenses and ongoing cost optimisation efforts
- Revenue down 14.3% to $25.2 million reflecting continued absence of new cord blood collections in Singapore
- Gross profit margin improves to 58.1% from 57.8% last year

Financial Highlights (unaudited)

S$'000	9M2026	9M2025	Change (%)
Revenue	25,178	29,394	(14.3)
Gross profit	14,625	16,994	(13.9)
Loss before income tax from operations	(5,797)	(7,512)	(22.8)
Loss before tax	(5,727)	(6,701)	(14.5)
Income tax expense	(64)	(382)	(83.2)
Net loss	(5,791)	(7,083)	(18.2)
Gross profit margin (%)	58.1	57.8	0.3 pp
Net profit margin (%)	(23.0)	(24.1)	1.1 pp

*pp = percentage points

Singapore, 13 November 2026 – Cordlife Group Limited ("Cordlife" or the "Company", and together with its subsidiaries, the "Group") today announced its financial results for the nine months ended 30 September 2026 ("9M2026"). Revenue declined 14.3% to $25.2 million from $29.4 million in the corresponding period last year, primarily reflecting continued absence of new cord blood collections in Singapore.

Gross profit declined 13.9% to $14.6 million from $17 million in 9M2025. Gross profit margin improved slightly to 58.1% from 57.8%.

The Group continued to exercise cost discipline during the period with selling and marketing expenses fell 28.5% to $8.4 million, reflecting reduced marketing activity in Singapore following the suspension of new cord blood collections and administrative expenses decreased 9.1% to $13.8 million. These reductions contributed to the narrowing of the Group's net loss by 18.2% to $5.8 million from $7.1 million in 9M2025.

As at 30 September 2026, the Group maintains a healthy balance sheet, with $57.3 million in cash and cash equivalents, fixed deposits and short-term investments.

Cordlife Singapore's cord blood banking and human tissue banking licenses were renewed by the Ministry of Health in January 2026. However, new cord blood collections remain suspended under the conditions imposed in November 2025. The Group continues to work closely with the regulators and remains focused on fulfilling the remaining requirements for the resumption of new cord blood collections in Singapore.

Hong Kong remained the Group's largest market, contributing revenue of $7.4 million in 9M2026. During the period, HealthBaby in Hong Kong achieved its seventh accreditation from the College of American Pathologists (CAP) in June 2026, followed by Cordlife Hong Kong's eighth accreditation from the Association for the Advancement of Blood & Biotherapies (AABB) in July 2026 and Cordlife India's sixth CAP accreditation in August 2026. These achievements reaffirm the Group's commitment to maintaining internationally recognised quality standards across its operations.

Cordlife Group Limited
1 Yishun Industrial Street 1 • A'Posh Bizhub • #06-01/09 • Singapore 768160
Phone (65) 6238 0808 • Fax (65) 6238 1108
Find Out More • info@cordlife.com • For Cordlife Parents • customercare@cordlife.com
Company Registration Number: 200102883E

The legal proceedings arising from FY2023 temperature excursion and the assessment of the remaining low-risk cryogenic storage tanks remain ongoing. The Group will continue to monitor developments and provide updates where appropriate.

Cordlife Group CEO Chen Xiaoling said: “The past year has been about stabilising the business and addressing the issues in Singapore. We have strengthened our operations, sharpened our focus on our core business and improved cost discipline across the Group.

“Our priority in the coming months is to meet the remaining regulatory requirements in Singapore and recover the trust and confidence of our stakeholders.

“We believe the long-term needs for cord blood banking remain intact, supported by growing awareness of preventive healthcare and advances in cell-based therapies. Our focus is to ensure the Group is well positioned to capture growth opportunities while continuing to improve our operational processes and governance.”

Looking ahead, growing awareness of preventive healthcare and continued advances in cell-based therapies are expected to support long-term demand for cord blood banking. The Group remains focused on strengthening its core cord blood banking business, maintaining regulatory compliance across its markets and preserving financial discipline. In Singapore, management continues to prioritise the fulfilment of the remaining regulatory requirements needed for the resumption of new cord blood collections.

While macroeconomic conditions, consumer confidence and regulatory developments may affect demand over the next 12 months, the Group believes the long-term fundamentals of the industry remain positive.

- End -

Cordlife Group Limited
1 Yishun Industrial Street 1 • A'Posh Bizhub • #06-01/09 • Singapore 768160
Phone (65) 6238 0808 • Fax (65) 6238 1108
Find Out More • info@cordlife.com • For Cordlife Parents • customercare@cordlife.com
Company Registration Number: 200102883E

ABOUT CORDLIFE GROUP LIMITED

Established in May 2001, Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group") is a leading company dedicated to safeguarding the well-being of mother and child. The Group has been listed on the Mainboard of the Singapore Exchange since 2012 and is a pioneer in private cord blood banking in Asia. Cordlife owns the largest network of cord blood banks in Asia with full stem cell banking facilities and direct operations in six key markets namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, Hong Kong, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks and it is amongst the top three market leaders in India and Malaysia. In January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank, Healthbaby Biotech (Hong Kong) Co., Limited. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife holds an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife has also established its presence in Myanmar, Vietnam, Macau, Brunei and Bangladesh. Beyond cord blood, cord lining and cord tissue banking, Cordlife offers a comprehensive suite of diagnostic services for the family including urine-based newborn metabolic screening, non-invasive prenatal testing, and family genetic screening services. Quality and customer focus are amongst some of the cornerstones of Cordlife. For more information, visit http://cordlife.listedcompany.com

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : Catherine Ong Associates

3 Pickering Street, #02 - 01, Nankin Row

China Square Central

Singapore 048660

CONTACT : Romesh Navaratnarajah

EMAIL : romesh@catherineong.com